scholarly journals Soluble CCL5 Derived from Bone Marrow-Derived Mesenchymal Stem Cells and Activated by Amyloid β Ameliorates Alzheimer's Disease in Mice by Recruiting Bone Marrow-Induced Microglia Immune Responses

Stem Cells ◽  
2012 ◽  
Vol 30 (7) ◽  
pp. 1544-1555 ◽  
Author(s):  
Jong Kil Lee ◽  
Edward H. Schuchman ◽  
Hee Kyung Jin ◽  
Jae-Sung Bae
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Immune Responses ◽  
Amyloid Β

Therapeutic effects of melatonin-treated bone marrow mesenchymal stem cells (BMSC) in a rat model of Alzheimer's disease

2020 ◽  
Vol 108 ◽  
pp. 101804
Author(s):  
Mahdi Ramezani ◽  
Alireza Komaki ◽  
Nasrin Hashemi-Firouzi ◽  
Keywan Mortezaee ◽  
Nafiseh Faraji ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Rat Model ◽  
Therapeutic Effects ◽  
Model Of Alzheimer’S Disease ◽  
Marrow Mesenchymal Stem Cells

Subcutaneous Administration of AMD3100 into Mice Models of Alzheimer’s Disease Ameliorated Cognitive Impairment, Reduced Neuroinflammation, and Improved Pathophysiological Markers

2020 ◽  
Vol 78 (2) ◽  
pp. 653-671
Author(s):  
Yuval Gavriel ◽  
Inna Rabinovich-Nikitin ◽  
Assaf Ezra ◽  
Becki Barbiro ◽  
Beka Solomon
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Stem Cells ◽  
Bone Marrow ◽  
Cognitive Impairment ◽  
Combined Treatment ◽  
Amyloid Β ◽  
Bone Marrow Niche ◽  
Hematopoietic Stem ◽  
The Brain

Background: Alzheimer’s disease (AD), the prevalent dementia in the elderly, involves many related and interdependent pathologies that manifest simultaneously, leading to cognitive impairment and death. Amyloid-β (Aβ) accumulation in the brain triggers the onset of AD, accompanied by neuroinflammatory response and pathological changes. The CXCR4/CXCL12 (SDF1) axis is one of the major signal transduction cascades involved in the inflammation process and regulation of homing of hematopoietic stem cells (HSCs) within the bone marrow niche. Inhibition of the axis with AMD3100, a reversible antagonist of CXCR4 mobilizes endogenous HSCs from the bone marrow into the periphery, facilitating the recruitment of bone marrow-derived microglia-like cells into the brain, attenuates the neuroinflammation process that involves release of excitotoxic markers such as TNFα, intracellular Ca2 +, and glutamate and upregulates monocarboxylate transporter 1, the major L-lactate transporter in the brain. Objective: Herein, we investigate if administration of a combination of AMD3100 and L-lactate may have beneficial effects in the treatment of AD. Methods: We tested the feasibility of the combined treatment for short- and long-term efficacy for inducing endogenous stem cells’ mobilization and attenuation of neuroinflammation in two distinct amyloid-β-induced AD mouse models. Results: The combined treatment did not demonstrate any adverse effects on the mice, and resulted in a significant improvement in cognitive/memory functions, attenuated neuroinflammation, and alleviated AD pathologies compared to each treatment alone. Conclusion: This study showed AMD3100’s beneficial effect in ameliorating AD pathogenesis, suggesting an alternative to the multistep procedures of transplantation of stem cells in the treatment of AD.

Potential of bone marrow mesenchymal stem cells in management of Alzheimer's disease in female rats

2014 ◽  
Vol 38 (12) ◽  
pp. 1367-1383 ◽  
Author(s):  
Ahmed M. Salem ◽  
Hanaa H. Ahmed ◽  
Hazem M. Atta ◽  
Mohamed A. Ghazy ◽  
Hadeer A. Aglan
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Female Rats ◽  
Marrow Mesenchymal Stem Cells

Therapeutic effect of mesenchymal stem cells in an animal model of Alzheimer’s disease evaluated by β-amyloid positron emission tomography imaging

2020 ◽  
Vol 54 (9) ◽  
pp. 883-891
Author(s):  
Bok-Nam Park ◽  
Jang-Hee Kim ◽  
Tae Sung Lim ◽  
So Hyun Park ◽  
Tae-Gyu Kim ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Positron Emission Tomography ◽  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Standardized Uptake Value ◽  
Emission Tomography ◽  
Positron Emission ◽  
Β Amyloid

Objective: We evaluated the effects of bone marrow–derived mesenchymal stem cells in a model of Alzheimer’s disease using serial [18F]Florbetaben positron emission tomography. Methods: 3xTg Alzheimer’s disease mice were treated with intravenously injected bone marrow–derived mesenchymal stem cells, and animals without stem cell therapy were used as controls. Serial [18F]Florbetaben positron emission tomography was performed after therapy. The standardized uptake value ratio was measured as the cortex standardized uptake value divided by the cerebellum standardized uptake value. Memory function and histological changes were observed using the Barnes maze test and β-amyloid-reactive cells. Results: Standardized uptake value ratio decreased significantly from day 14 after stem cell administration in the bone marrow–derived mesenchymal stem cells–treated group ( n = 28). In contrast, there was no change in the ratio in control mice ( n = 25) at any time point. In addition, mice that received bone marrow–derived mesenchymal stem cell therapy also exhibited significantly better memory function and less β-amyloid-immunopositive plaques compared to controls. Conclusion: The therapeutic effect of intravenously injected bone marrow–derived mesenchymal stem cells in a mouse model of Alzheimer’s disease was confirmed by β-amyloid positron emission tomography imaging, memory functional studies and histopathological evaluation.

Sign in / Sign up

Export Citation Format

Share Document